

Your lanreotide treatment plan

Patient Record

Your name:

Compassionate Aspirational Resourceful Excellent

You are about to commence a course of lanreotide injections. This record will help you to remember your appointments.

Your treatment

Lanreotide or Somatuline autogel is a treatment given to help control the symptoms of flushing and diarrhoea often experienced with carcinoid tumours. It is given as an injection into the buttock. Your oncologist (cancer specialist) will discuss what frequency and dose would be best for you before starting the treatment.

This is usually every four weeks but sometimes every three weeks. You will need to be seen on average every three to six months by your oncologist to discuss how you are and to see whether any changes are required. You will need to have a blood test six weeks before your appointment with the doctor.

Side effects

If you are experiencing any side effects, please discuss them with your oncologist or nurse specialist. Lanreotide is known to have few side effects but you need to seek medical advice if you experience swelling of your tongue, lips or face after the injection. There is also a chance that the medication could make you feel dizzy. If it does, please do not drive or operate machinery until the dizziness has passed.

If you require urgent medical attention out of normal working hours (Monday-Friday 9am-5pm), please call NHS 111 to arrange to go to your local Emergency Department (A&E) and tell them that you are having this treatment (lanreotide).

Your treatment plan

Treatment	Туре	Date
1		
2		
3		
4		
E		
5		
6		
7		
8		
9		
10		

Treatment	Туре	Date
11		
12		
13		
14		
15		

Contact us

- King Edward Ward, Royal Berkshire Hospital, Tel: 0118 322 7464
- Chemotherapy 1, Bracknell Clinic, Tel: 01344 662907
- Berkshire Cancer Centre Clinic Appointments, Tel: 0118 322 7888

To find out more about our Trust visit www.royalberkshire.nhs.uk

Please ask if you need this information in another language or format.

Chemotherapy, BCC, May 2023

Next review due: May 2025